Category : Cancer Research

Eric Lefkofsky and Tempus Labs – Leading the Way in the Democratization of Information Access

Eric Lefkofsky believes in the power of collaboration and his belief in collaboration guides the success of Tempus Lab. Founded in 2015, Tempus Labs is a business startup that developed an operating system with the end goal of battling cancer. Tempus Labs is a collaborative venture involving healthcare professionals, scientists, technologists, etc. to affect positively the lives of patients living with cancer. Lefkofsky believes it is only through collaboration that we can aggressively champion for cancer patients through democratizing information. He believes many researchers work in silos and rather than share information, information is hoarded and not used to benefit humankind. Tempus Labs is leading the way in democratizing information and the access to information.

The collaboration between scientists, researchers, and physicians at Tempus Labs has led to its success. As a team effort, Tempus Labs developed an operating system that personalizes patient care through an “interactive analytical and machine learning platform.” Through genomic sequencing, Tempus Labs is revolutionizing cancer care. In a published article, Lefkofsky stated a true revolution in medicine is possible through the integration of millions of molecular profiles and clinical data.

The cutting-edge work of Tempus Labs has not gone unnoticed. In a recent Chicago Tribune article, it was reported that Eric Lefkofsky and Tempus Labs recently received an $80 million investment. Since 2015, Tempus Labs has received more than $210 million in investment dollars, increasing its valuation to $1.1 billion. Crossing that $1 billion threshold earned Tempus Labs the enviable title of “unicorn,” a term reserved for startups that pass the $1 billion mark in total valuation.

Eric Lefkofsky’s entrepreneurial spirit has not been limited to Tempus Labs. In addition to Tempus Labs, Eric is the founder and partner of Lightbank, “a venture fund investing in disruptive technologies.” He is also co-founder and chair of Groupon and co-founder of Uptake Technologies, “a leading predictive analytics platform for the world’s largest industries.”

Eric along with his wife Liz, give back to the community through their Lefkofsky Family Foundation, extending his goal to enhance life through philanthropy.

For details: www.lightbank.com/team/eric-lefkofsky


Clay Siegal: Researching for Biotechnology Innovation

Seattle Genetics has been studying the potential of human antibodies for years. The company has been conducting a lot of research which focuses on the manipulation of human antibodies to make a product out of it. Since their establishment in 1998, Seattle Genetics has successfully created products made from human antibodies that are beneficial to people. Through their researchers, the company found out that human antibodies can bond with substances found inside the body. Depending on the material that they have made connections with, human antibodies can create a toxin that can destroy cancer cells. The research that they made is considered as a scientific breakthrough, and it made it possible for Seattle Genetics to create medications that can treat some cancer diseases.

Clay Siegal is one of the co-founders of Seattle Genetics, and he is also serving as the present chairman, president, and CEO of the company. Since the creation of products that can treat cancer, the value of Seattle Genetics spiked, and experts are saying that the company is currently valued at more than $10 billion. Almost 900 people are working for Seattle Genetics, and through the effort of Clay Siegal and the cooperation of the employees working for the company, they were recognized as one of the most competitive and prominent biotech companies in Washington. However, Clay Siegal does not want to stay being known in his home state, because one of his dreams is for the company to gain national recognition. He is doing everything that he can to transform the business from a small biotech company to one of the leading pharmaceutical companies in the country.

Seattle Genetics has released several products which they advertise as an active drug to combat cancer. The company’s flagship product is Adcetris and based on studies; the medication can treat Hodgkin Lymphoma, a mild type of cancer victimizing millions of people worldwide. It affects the lymphatic system, and it can become deadly if neglected. Adcetris destroys the cancer cells for those who are affected by the disease, and Clay Siegal believes that their products are the precursors to the most awaited cure for cancer.